Physiotherapy Equipment Market to Surpass $9.45B by 2029
The physiotherapy equipment market generated $6.26 billion in 2023, is estimated at $6.70 billion for 2024, and is projected...
Longeveron Alzheimer’s Data Selected for CTAD Presentation
Longeveron will present new CLEAR MIND study results indicating reductions in brain neuroinflammation following treatment with laromestrocel (Lomecel-B) in...
Breakthrough TARA-002 Trial Sees Positive Pediatric Results
In an interim readout from the Phase 2 STARBORN-1 trial in pediatric lymphatic malformations, 100% of the eight patients...
NIH Funds Trial for Non-Surgical Knee Osteoarthritis Relief
Steadman Philippon Research Institute and Neuromuscular Dynamics have initiated a randomized, at-home trial in knee osteoarthritis testing an eight-week...
Kyowa Kirin Presents New Mogamulizumab Research at ASH 2025
No efficacy or safety rates were disclosed ahead of ASH, but the headline is a Phase 2, single-arm evaluation...
Radiopharm Begins Promising Phase 1 Prostate Cancer Trial
Radiopharm Theranostics has received ethics approval from Australia’s Bellberry HREC to initiate a first-in-human Phase 1 study of RAD...
Annovis Announces FDA Meeting for Parkinson’s, Alzheimer’s
No new efficacy or safety data accompanied Annovis Bio’s update. The company reported two regulatory developments: FDA has scheduled...
HCW Biologics Begins First-in-Human Trial for Autoimmunity
HCW Biologics has dosed the first patient in its multi-center, first-in-human Phase 1 trial of HCW9302 (NCT07049328) in alopecia...
Navepegritide Trial Results for Children with Achondroplasia
TransCon CNP (navepegritide) met the primary endpoint in the 52-week, randomized, double-blind ApproaCH trial, delivering a statistically significant increase...
T-Knife Files for Phase 1 Trial of PRAME T-Cell Therapy
No clinical data were disclosed. The update centers on a regulatory filing to begin first-in-human testing and preclinical evidence...